Crispr Therapeutics AG (CRSP) AI Stock Analysis

• Market Cap: $5.77B
• Dividend Yield: N/A
• Average Volume (3M): 1.62M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: -81.10%
• EPS Growth: -99.21%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.37
• Shares Outstanding: 95,985,310
• 10 Day Avg. Volume: 1,552,596
• 30 Day Avg. Volume: 1,623,708
• PEG Ratio: -0.17
• Price to Book (P/B): 2.45
• Price to Sales (P/S): 1343.50
• P/FCF Ratio: -13.63
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 2.22K
• Enterprise Value/Gross Profit: -25.94
• Enterprise Value/Ebitda: -9.39
• 1Y Price Target: $70.21
• Price Target Upside: 13.73% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): -4.84
• Revenue Forecast (FY): $48.95M

• Rating: 47 Neutral
• Price Target: $59.00 ▼(-4.44% Downside)
• Action: Reiterated Date: 02/14/26
• Date: Action: Reiterated 02/14/26

The score is held down primarily by weak and volatile financial performance (episodic collaboration revenue, large losses, and ongoing cash burn) and a bearish technical setup (price below key moving averages with negative MACD). Offsetting factors include a comparatively strong, low-leverage balance sheet and a positive pipeline/corporate update that supports longer-term potential, but valuation is not supported by profitability (negative P/E) and there is no dividend yield.

Positive Factors

Strong balance sheet / low leverage

Low debt and a sizeable equity base give Crispr financial flexibility and runway to fund clinical programs and commercialization without immediate reliance on dilutive financing. That durability supports multi‑year R&D and regulatory timelines common in gene‑editing biotech.

Broad, advancing pipeline

Progress across in vivo editing, Lp(a)/lipid programs, CAR‑T (zugo‑cel) and regenerative diabetes candidates diversifies binary clinical risk. Multiple programs entering later‑stage readouts increase the probability of durable value creation versus a single‑asset biotech.

Commercial traction and partner collaborations

Having a commercial product (CASGEVY) plus revenue‑linked collaborations and external partnerships provides recurring and milestone revenue potential and leverages partners' commercialization/regulatory capabilities, reducing sole execution risk over the medium term.

Negative Factors

Highly volatile, milestone-driven revenue

Dependence on irregular collaboration and milestone payments creates lumpy revenue that undermines predictable cash generation and planning. A large revenue collapse in 2025 highlights that until product sales scale, top‑line remains contingent on often unpredictable partner milestones.

Ongoing negative cash flow / cash burn

Sustained negative operating and free cash flow forces reliance on external capital or partnerships to fund trials and commercialization. Repeated fundraising risks dilution, raises financing costs, and constrains the company’s ability to scale commercial operations if clinical timelines slip.

Persistent deep losses and negative margins

Consistent negative margins and losses erode returns on equity and can deplete capital over time. Unless clinical successes translate into sustained product revenue, persistent losses limit flexibility to invest in multiple programs and increase dependence on partners or dilutive financing.

Crispr Therapeutics AG Business Overview & Revenue Model

Company Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

How the Company Makes Money

Crispr Therapeutics generates revenue through several key streams. The primary source of income comes from partnerships and collaborations with other pharmaceutical and biotechnology companies, which often involve upfront payments, milestone payments, and royalties on sales of products developed using Crispr's technology. Additionally, the company may earn revenue through licensing agreements for its proprietary technology. As therapies progress through clinical trials and receive regulatory approvals, potential commercialization can lead to significant revenue through product sales. Furthermore, research grants and investments can also contribute to the company's financial resources.

Crispr Therapeutics AG Financial Statement Overview

Summary

Overall fundamentals are weak despite a solid balance sheet. Income statement quality is poor due to highly volatile, milestone-driven revenue (2025 revenue down ~90% vs. 2024) and continued deep losses, while cash flow remains mostly negative with ongoing cash burn. The main offset is a relatively strong balance sheet with modest leverage and stable equity, providing runway, but persistent negative returns and inconsistent profitability keep the score low.

Income Statement

Revenue has been highly volatile and recently collapsed (2025 revenue down ~90% vs. 2024), highlighting dependence on irregular collaboration or milestone income. Profitability is weak: the company is deeply loss-making in 2022–2025 with very negative gross and net margins in the latest year, and operating losses expanded again in 2025. A key positive is that 2021 showed the model can be profitable when revenue events occur, but the lack of consistency and the sharp 2025 deterioration weigh heavily on the score.

Balance Sheet

The balance sheet is a relative strength: leverage is modest with debt-to-equity staying low (~0.09–0.13 across the period) and equity remains large versus total debt, providing financial flexibility. Total assets and equity have been broadly stable, suggesting the company has been able to fund operations without heavy debt. The main weakness is persistent negative returns on equity in most years (except 2021), reflecting ongoing losses that can erode capital over time if not reversed.

Cash Flow

Cash generation is a concern: operating cash flow and free cash flow are negative in most years (2020, 2022–2025), indicating ongoing cash burn. While 2025 free cash flow improved versus 2024 (positive growth rate) and free cash flow has generally tracked net income (losses), the business still requires funding support until operations turn sustainably cash-positive. The standout strength is 2021, when operating and free cash flow were strongly positive, but that performance has not been sustained.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.51M	35.00M	370.00M	436.00K	913.08M
Gross Profit	-229.45M	-75.25M	239.75M	-109.81M	811.90M
EBITDA	-548.84M	-447.31M	-202.70M	-648.99M	391.48M
Net Income	-581.60M	-366.25M	-153.61M	-650.17M	377.66M
Balance Sheet
Total Assets	2.27B	2.24B	2.23B	2.24B	2.75B
Cash, Cash Equivalents and Short-Term Investments	1.98B	1.90B	1.69B	1.82B	2.38B
Total Debt	394.91M	223.69M	238.63M	244.02M	225.03M
Total Liabilities	343.43M	309.95M	346.77M	367.58M	352.42M
Stockholders Equity	1.92B	1.93B	1.88B	1.88B	2.40B
Cash Flow
Free Cash Flow	-345.93M	-144.68M	-269.85M	-532.93M	457.27M
Operating Cash Flow	-345.01M	-142.77M	-260.38M	-495.74M	538.97M
Investing Cash Flow	-31.80M	-280.48M	374.65M	-258.65M	-1.04B
Financing Cash Flow	426.03M	331.98M	62.66M	38.59M	250.94M

Crispr Therapeutics AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 61.74
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Positive. The current price of 61.74 is above the 20-day moving average (MA) of 52.48, above the 50-day MA of 54.15, and above the 200-day MA of 54.76, indicating a bullish trend. The MACD of 1.32 indicates Negative momentum. The RSI at 62.23 is Neutral, neither overbought nor oversold. The STOCH value of 84.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRSP.

Crispr Therapeutics AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KYMR	64 Neutral	$7.46B	-24.83	-32.09%	―	-50.05%	-54.47%
BEAM	63 Neutral	$2.90B	-28.02	-8.11%	―	-84.07%	-157.71%
APLS	58 Neutral	$2.68B	169.72	7.48%	―	42.11%	―
NTLA	54 Neutral	$1.63B	-3.60	-53.48%	―	33.52%	21.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LEGN	50 Neutral	$3.51B	-14.55	-22.60%	―	74.91%	31.54%
CRSP	47 Neutral	$5.77B	-9.23	-30.18%	―	-81.10%	-99.21%

Crispr Therapeutics AG Corporate Events

CRISPR Therapeutics Highlights Pipeline Advances in Gene-Edited Therapies

On January 12, 2026, CRISPR Therapeutics issued an update on its pipeline, underscoring progress across in vivo gene editing, cell therapy and regenerative medicine programs. In 2025, the company reported positive Phase 1 data for CTX310, showing deep and durable reductions in triglycerides and LDL cholesterol after a single IV dose with a favorable safety profile, and has moved the ANGPTL3-targeting therapy into Phase 1b trials for severe hypertriglyceridemia and refractory hypercholesterolemia. CTX320, targeting LPA, has yielded up to 73% reductions in the dose-escalation phase, while next-generation LPA candidate CTX321, designed with a more potent guide RNA and the same LNP platform, is in IND/CTA-enabling studies alongside CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency, reflecting a broadening cardiovascular and metabolic portfolio. The company also highlighted progress for its CAR-T candidate zugocabtagene geleucel (zugo-cel) in autoimmune diseases and B-cell malignancies, with early systemic lupus erythematosus data showing sustained drug-free clinical remission and B-cell depletion in heavily pretreated patients, and an expanded oncology strategy via a collaboration with Eli Lilly to test zugo-cel with pirtobrutinib in aggressive B-cell lymphomas. In regenerative medicine, CRISPR Therapeutics reported promising 12‑month C-peptide data from diabetes candidate CTX211 that are guiding a shift toward next-generation hypoimmune cell therapy CTX213, which has shown strong preclinical efficacy and is being advanced toward clinical testing, signaling the company’s intent to consolidate its position as a leading player in gene-edited therapies across multiple high-need disease areas.

The most recent analyst rating on (CRSP) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.